Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 8;76(3):e495-e498.
doi: 10.1093/cid/ciac652.

Impact of Seasonal Coronavirus Antibodies on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Responses in Solid Organ Transplant Recipients

Andrew H Karaba  1 , Weiqiang Zhou  2 , Shuai Li  2 , Tihitina Y Aytenfisu  1 , Trevor S Johnston  1 , Olivia Akinde  3 , Yolanda Eby  3 , Aura T Abedon  4 , Jennifer L Alejo  4 , Caroline X Qin  4 , Elizabeth A Thompson  1 , Jacqueline M Garonzik-Wang  5 , Joel N Blankson  1 , Andrea L Cox  1   6   7 , Justin R Bailey  1 , Sabra L Klein  6 , Andrew Pekosz  6 , Dorry L Segev  4   8 , Aaron A R Tobian  3 , William A Werbel  1
Affiliations

Impact of Seasonal Coronavirus Antibodies on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Responses in Solid Organ Transplant Recipients

Andrew H Karaba et al. Clin Infect Dis. .

Erratum in

Abstract

Antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination are reduced in solid organ transplant recipients (SOTRs). We report that increased levels of preexisting antibodies to seasonal coronaviruses are associated with decreased antibody response to SARS-CoV-2 vaccination in SOTRs, supporting that antigenic imprinting modulates vaccine responses in SOTRs.

Keywords: COVID-19; SARS-CoV-2; immunocompromised hosts; vaccines.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. D. L. S. reports consulting and speaking honoraria from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, Regeneron, AstraZeneca, and Thermo Fisher Scientific; consulting fees from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, Thermo Fisher Scientific, Regeneron, and AstraZeneca; and speaking honoraria from Sanofi and Novartis (paid to author). A. L. C. reports consulting fees from Janssen. A. H. K. reports consulting fees from Roche. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Publication types